[Usefulness of the determination of 5NU together with CA 19-9 in the diagnosis and monitoring of dyskaryokinetic liver diseases].
Santini
D
D
Dipartimento Med. Sperimentale, Policlinico Umberto I, Roma.
Marchei
G G
GG
Trasatti
L
L
Di Seri
M
M
Reale
M G
MG
Frati
I
I
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008107:Liver Diseases / Q000097:blood* / Q000473:pathology; D008113:Liver Neoplasms / Q000097:blood* / Q000473:pathology; D008938:Mitosis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor
Utilità del dosaggio del 5NU unitamente al CA 19-9 nella diagnostica e nel monitoraggio delle affezioni epatiche discariocinetiche.